共 11 条
[1]
Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: Serious concerns over the reliability of the PLATO trial[J] . James J. DiNicolantonio,Ales Tomek.International Journal of Cardiology . 2013
[3]
Ticagrelor Enhances Adenosine-induced Coronary Vasodilatory Responses in Humans[J] . Journal of the American College of Cardiology . 2012
[6]
Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes[J] . Jose Diez,B Lombo.Core Evidence . 2011 (defa)
[7]
Incidence of Dyspnea and Assessment of Cardiac and Pulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor, Clopidogrel, or Placebo in the ONSET/OFFSET Study[J] . Robert F. Storey,Kevin P. Bliden,Shankar B. Patil,Arun Karunakaran,Rosemary Ecob,Kathleen Butler,Renli Teng,Cheryl Wei,Udaya S. Tantry,Paul A. Gurbel.Journal of the American College of Cardiology . 2010 (3)
[8]
Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study[J] . Paul A. Gurbel,Kevin P. Bliden,Kathleen Butler,Mark J. Antonino,Cheryl Wei,Renli Teng,Lars Rasmussen,Robert F. Storey,Tonny Nielsen,John W. Eikelboom,Georges Sabe-Affaki,Steen Husted,Dean J. Kereiakes,David Henderson,Dharmendra V. Patel,Udaya S. Tantry.Circulation . 2010 (10)
[9]
Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET Study[J] . Paul A. Gurbel,Kevin P. Bliden,Kathleen Butler,Udaya S. Tantry,Tania Gesheff,Cheryl Wei,Renli Teng,Mark J. Antonino,Shankar B. Patil,Arun Karunakaran,Dean J. Kereiakes,Cordel Parris,Drew Purdy,Vance Wilson,Gary S. Ledley,Robert F. Storey.Circulation . 2009 (25)
[10]
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)[J] . Stephen D. Wiviott,Elliott M. Antman,C. Michael Gibson,Gilles Montalescot,Jeffrey Riesmeyer,Govinda Weerakkody,Kenneth J. Winters,Jeffrey W. Warmke,Carolyn H. McCabe,Eugene Braunwald.American Heart Journal . 2006 (